Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gina L Mazza

Showing results (1-10 of 56) with videos related to

Pageof 6
Sort By:
Journal of the National Cancer Institute|July 2, 2025
Expected versus observed effect sizes for survival endpoints in phase 3 oncology trialsSophia J Lamp, Gina L Mazza
Developmental Psychology|October 31, 2017
Trajectories of familism values and the prosocial tendencies of Mexican American adolescentsGeorge P Knight, Gina L Mazza, Gustavo Carlo
Multivariate Behavioral Research|June 22, 2019
A Viable Alternative When Propensity Scores Fail: Evaluation of Inverse Propensity Weighting and Sequential G-Estimation in a Two-Wave Mediation ModelMatthew J Valente, David P MacKinnon, Gina L Mazza
Multivariate Behavioral Research|November 27, 2015
Addressing Item-Level Missing Data: A Comparison of Proration and Full Information Maximum Likelihood EstimationGina L Mazza, Craig K Enders, Linda S Ruehlman
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 12, 2020
Investigation Into the Effects of Using Normal Distribution Theory Methodology for Likert Scale Patient-Reported Outcome Data From Varying Underlying Distributions Including Floor/Ceiling EffectsTodd A DeWees, Gina L Mazza, Michael A Golafshar, et al.
Journal of the National Cancer Institute. Monographs|February 24, 2025
Design and analysis considerations for investigating patient subgroups of interest within cancer clinical trialsGina L Mazza, Eva Culakova, Danielle M Enserro, et al.
Journal of Hematology|November 22, 2021
Validation of a Modified Version of the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom ScoreBlake T Langlais, Gina L Mazza, Heidi E Kosiorek, et al.
Prevention Science : the Official Journal of the Society for Prevention Research|March 31, 2017
Attendance Trajectory Classes Among Divorced and Separated Mothers and Fathers in the New Beginnings ProgramAnne M Mauricio, Gina L Mazza, Cady Berkel, et al.
Evaluation & the Health Professions|April 12, 2018
Multigroup Propensity Score Approach to Evaluating an Effectiveness Trial of the New Beginnings ProgramJenn-Yun Tein, Gina L Mazza, Heather J Gunn, et al.
The Lancet. Haematology|December 31, 2021
Symptom burden and quality of life in patients with high-risk essential thrombocythaemia and polycythaemia vera receiving hydroxyurea or pegylated interferon alfa-2a: a post-hoc analysis of the MPN-RC 111 and 112 trialsGina L Mazza, Carolyn Mead-Harvey, John Mascarenhas, et al.
Pageof 6

Showing results (1-10 of 56) with videos related to

Sort By:
Pageof 6
Journal of the National Cancer Institute|July 2, 2025
Expected versus observed effect sizes for survival endpoints in phase 3 oncology trialsSophia J Lamp, Gina L Mazza
Developmental Psychology|October 31, 2017
Trajectories of familism values and the prosocial tendencies of Mexican American adolescentsGeorge P Knight, Gina L Mazza, Gustavo Carlo
Multivariate Behavioral Research|June 22, 2019
A Viable Alternative When Propensity Scores Fail: Evaluation of Inverse Propensity Weighting and Sequential G-Estimation in a Two-Wave Mediation ModelMatthew J Valente, David P MacKinnon, Gina L Mazza
Multivariate Behavioral Research|November 27, 2015
Addressing Item-Level Missing Data: A Comparison of Proration and Full Information Maximum Likelihood EstimationGina L Mazza, Craig K Enders, Linda S Ruehlman
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 12, 2020
Investigation Into the Effects of Using Normal Distribution Theory Methodology for Likert Scale Patient-Reported Outcome Data From Varying Underlying Distributions Including Floor/Ceiling EffectsTodd A DeWees, Gina L Mazza, Michael A Golafshar, et al.
Journal of the National Cancer Institute. Monographs|February 24, 2025
Design and analysis considerations for investigating patient subgroups of interest within cancer clinical trialsGina L Mazza, Eva Culakova, Danielle M Enserro, et al.
Journal of Hematology|November 22, 2021
Validation of a Modified Version of the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom ScoreBlake T Langlais, Gina L Mazza, Heidi E Kosiorek, et al.
Prevention Science : the Official Journal of the Society for Prevention Research|March 31, 2017
Attendance Trajectory Classes Among Divorced and Separated Mothers and Fathers in the New Beginnings ProgramAnne M Mauricio, Gina L Mazza, Cady Berkel, et al.
Evaluation & the Health Professions|April 12, 2018
Multigroup Propensity Score Approach to Evaluating an Effectiveness Trial of the New Beginnings ProgramJenn-Yun Tein, Gina L Mazza, Heather J Gunn, et al.
The Lancet. Haematology|December 31, 2021
Symptom burden and quality of life in patients with high-risk essential thrombocythaemia and polycythaemia vera receiving hydroxyurea or pegylated interferon alfa-2a: a post-hoc analysis of the MPN-RC 111 and 112 trialsGina L Mazza, Carolyn Mead-Harvey, John Mascarenhas, et al.
Pageof 6